She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

The head of the U.N. AIDS agency says Donald Trump should enable the American company Gilead to roll out its prevention drug ...

By Gift BritonThe once-a-year injectable pre-exposure prophylaxis (PrEP), Lenacapavir, has shown promising results in a recent Phase 1 clinical trial.The trial involved 40 healthy adults aged between ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

A recent trial has made a major advance against HIV, paving the way for a more streamlined prevention option. Existing methods for preventing HIV have been centered around daily oral drug use,. which ...